Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Michel Alonso

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|April 1, 2008
Corticosteroids for bacterial meningitisMuhamed-Kheir Taha, Jean-Michel Alonso
Human Vaccines|July 24, 2007
Meningococcal vaccines: to eradicate the disease, not the bacteriumMuhamed-Kheir Taha, Jean-Michel Alonso
La Revue Du Praticien|February 14, 2009
[Anti-meningococcal vaccines]Muhamed-Kheir Taha, Jean-Michel Alonso
Therapie|September 1, 2005
[Meningococcal vaccines: present status and perspectives]Jean-Michel Alonso, Muhamed-Kheir Taha
Research in Microbiology|February 5, 2008
Molecular epidemiology of infectious diseases: the example of meningococcal diseaseMuhamed-Kheir Taha, Jean-Michel Alonso
Medecine Sciences : M/S|November 5, 2004
[Immunoprophylaxis of respiratory infections]Christelle Dreffier, Françoise Ramisse, Jean-Michel Alonso
Emerging Infectious Diseases|August 6, 2008
Ciprofloxacin resistance in Neisseria meningitidis, FranceAnna Skoczynska, Jean-Michel Alonso, Muhamed-Kheir Taha
Expert Opinion on Emerging Drugs|July 24, 2009
Emerging drugs for acute bacterial meningitisAla-Eddine Deghmane, Jean-Michel Alonso, Muhamed-Kheir Taha
Infection and Immunity|September 22, 2006
Differential role of lipooligosaccharide of Neisseria meningitidis in virulence and inflammatory response during respiratory infection in miceMaria Leticia Zarantonelli, Michel Huerre, Muhamed-Kheir Taha, et al.
Journal of Clinical Microbiology|September 15, 2004
Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000Muhamed-Kheir Taha, Dario Giorgini, Magaly Ducos-Galand, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|April 1, 2008
Corticosteroids for bacterial meningitisMuhamed-Kheir Taha, Jean-Michel Alonso
Human Vaccines|July 24, 2007
Meningococcal vaccines: to eradicate the disease, not the bacteriumMuhamed-Kheir Taha, Jean-Michel Alonso
La Revue Du Praticien|February 14, 2009
[Anti-meningococcal vaccines]Muhamed-Kheir Taha, Jean-Michel Alonso
Therapie|September 1, 2005
[Meningococcal vaccines: present status and perspectives]Jean-Michel Alonso, Muhamed-Kheir Taha
Research in Microbiology|February 5, 2008
Molecular epidemiology of infectious diseases: the example of meningococcal diseaseMuhamed-Kheir Taha, Jean-Michel Alonso
Medecine Sciences : M/S|November 5, 2004
[Immunoprophylaxis of respiratory infections]Christelle Dreffier, Françoise Ramisse, Jean-Michel Alonso
Emerging Infectious Diseases|August 6, 2008
Ciprofloxacin resistance in Neisseria meningitidis, FranceAnna Skoczynska, Jean-Michel Alonso, Muhamed-Kheir Taha
Expert Opinion on Emerging Drugs|July 24, 2009
Emerging drugs for acute bacterial meningitisAla-Eddine Deghmane, Jean-Michel Alonso, Muhamed-Kheir Taha
Infection and Immunity|September 22, 2006
Differential role of lipooligosaccharide of Neisseria meningitidis in virulence and inflammatory response during respiratory infection in miceMaria Leticia Zarantonelli, Michel Huerre, Muhamed-Kheir Taha, et al.
Journal of Clinical Microbiology|September 15, 2004
Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000Muhamed-Kheir Taha, Dario Giorgini, Magaly Ducos-Galand, et al.
Pageof 4